Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study.
Saved in:
| Title: | Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study. |
|---|---|
| Authors: | Liao PW; Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Life Science, Tunghai University, Taichung, Taiwan., Ko BS; School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei City, Taiwan.; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan., Su YC; Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Nursing, Taichung Veterans General Hospital, Taichung, Taiwan., Chao WT; Department of Life Science, Tunghai University, Taichung, Taiwan., Teng CJ; Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Life Science, Tunghai University, Taichung, Taiwan.; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.; School of Medicine, Chung Shan Medical University, Taichung, Taiwan. |
| Source: | Cancer medicine [Cancer Med] 2026 Jun; Vol. 15 (6), pp. e72022. |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
